No clinically significant treatment effect modification was observed for the analysed endpoints, except for a numerical reduction in CV death in the younger patients treated with serelaxin which did not reach statistical significance ( p for interaction = 0.24 across age categories).
← all excerpts
Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX-AHF-2 trial.
1
—
—